Clinical trial / 2012
Long-term use of standardized Ginkgo biloba extract did not reduce the risk of progressing to Alzheimer's disease in elderly adults with memory complaints.
In the GuidAge trial, 2,854 adults aged 70 years or older with memory complaints were randomly allocated to receive 120 mg standardized Ginkgo biloba extract (EGb761) twice daily or placebo for 5 years. By 5 years, probable Alzheimer's disease was diagnosed in 61 participants in the ginkgo group (1.2 cases per 100 person-years) versus 73 in the placebo group (1.4 cases per 100 person-years; HR 0.84, 95% CI 0.60-1.18; p=0.306). Incidence of adverse events, all-cause deaths (76 vs 82; p=0.68), stroke (65 vs 60; RR 1.12, 95% CI 0.77-1.63; p=0.57), and other hemorrhagic or cardiovascular events did not differ significantly between groups.
- Study type
- Randomized, parallel-group, double-blind, placebo-controlled trial
- Who was studied
- 2,854 adults aged 70 years or older with spontaneous memory complaints in France
- What was measured
- Conversion to probable Alzheimer's disease over 5 years
THE PAPER
Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial.
Vellas B, Coley N, Ousset PJ, Berrut G, Dartigues JF, Dubois B, Grandjean H, Pasquier F, Piette F, Robert P, Touchon J, Garnier P, Mathiex-Fortunet H, Andrieu S, GuidAge Study Group. Lancet Neurol, 2012.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.